A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma

Part of paid clinical trials in San Francisco, California.

Sponsor
Jazz Pharmaceuticals
Study ID
NCT07533942
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Meningioma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JZP3507 — DRUG
    Participants will receive oral JZP3507 monotherapy twice daily, on 3 consecutive days per week in 28-day cycles.

Study Details

This study will recruit participants with Grade 2 and 3 meningiomas who have failed prior therapy. Participants will receive oral doses of JZP3507. The antitumor activity and safety of JZP3507 will be evaluated.

Key Dates

First listed
Apr 16, 2026
Start date
Jul 16, 2026
Status verified
Jul 2026
Primary completion
Oct 25, 2028
Completion
Oct 16, 2031

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: JZP3507 (ONC206)

Primary Outcome Measure

Overall Response Rate (ORR) as Assessed by Response Assessment in Neuro-Oncology (RANO) Criteria and Evaluated by Blinded Independent Central Review (BICR) [ Time Frame: From first dose until death, withdrawal of consent, or lost to follow-up, up to 36 months. ]

Central Contacts

Locations (5)

FacilityCityStateZIPSite coordinators
Sutter HealthSan FranciscoCalifornia94109-
Louisiana State UniversityNew OrleansLouisiana70112-
Mass GeneralBostonMassachusetts02114-
NYU- Langone HealthNew YorkNew York10016-
University of Utah - Huntsman Cancer InstituteSalt Lake CityUtah84112-

Find similar trials in San Francisco, CA

By research site
Sutter Health· San Francisco, CALouisiana State University· New Orleans, LAMass General· Boston, MANYU- Langone Health· New York, NYUniversity of Utah - Huntsman Cancer Institute· Salt Lake City, UT

Related Studies